Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Collaborator: McLaughlin-Rotman Center for Global Health, University of Toronto
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• Microscopically confirmed P.falciparum infection

• Age >18 years

• Able to tolerate oral therapy

• Able to give informed consent

Exclusion Criteria:

• Fulfillment of WHO criteria for severe/cerebral malaria

• Prior treatment with any thiazolidinedione

• Allergy to rosiglitazone

• History of diabetes mellitus

• History of severe/decompensated liver disease

• ALT level >2.5 times normal

• Current treatment for congestive heart failure

• Pregnancy or breastfeeding